Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European ...

Heating and air conditioning equipment maker Lennox International Inc. is replacing contract drug maker Catalent Inc. in the ...

Novo Nordisk ( (NVO) ) has provided an announcement.

Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the ...

The latest announcement is out from Catalent ( (CTLT) ).

New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines ...

Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days ...

Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion ...

Novo Holdings, parent company of the pharmaceutical giant Novo Nordisk, is spending $16.5 billion on the acquisition. The ...

Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...